🚀 VC round data is live in beta, check it out!
SenzaGen Valuation Multiples
Discover revenue and EBITDA valuation multiples for SenzaGen and similar public comparables like Biosynex, EBM Technologies, Diagnos, Immunovia and more.
SenzaGen Overview
About SenzaGen
SenzaGen AB markets sells, and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its laboratory and licensed Contract Research Organizations (CROs) in Sweden. It offers animal-free testing of chemical compounds in cosmetics, pharmaceuticals, food products, and dyes. It operates in five market segments- Cosmetics, Chemicals, Medical devices, Pharmaceuticals, and Nutrition/food additives. The majority is from the Pharmaceuticals segment. Geographically it operates in North America, Europe, APAC, and RoW, the majority is from Europe.
Founded
2010
HQ
Employees
34
Website
Financials (FY)
EV
$19M
SenzaGen Financials
SenzaGen reported last fiscal year revenue of $6M and negative EBITDA of ($1M).
In the same fiscal year, SenzaGen generated $4M in gross profit, ($1M) in EBITDA losses, and had net loss of ($1M).
SenzaGen P&L
In the most recent fiscal year, SenzaGen reported revenue of $6M and EBITDA of ($1M).
SenzaGen expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $6M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $4M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 65% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($1M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (18%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (20%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($1M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (20%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SenzaGen Stock Performance
SenzaGen has current market cap of $20M, and enterprise value of $19M.
Market Cap Evolution
SenzaGen's stock price is $0.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $19M | $20M | 0.3% | XXX | XXX | XXX | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSenzaGen Valuation Multiples
SenzaGen trades at 2.9x EV/Revenue multiple, and (16.1x) EV/EBITDA.
SenzaGen Financial Valuation Multiples
As of April 20, 2026, SenzaGen has market cap of $20M and EV of $19M.
Equity research analysts estimate SenzaGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SenzaGen has a P/E ratio of (15.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $20M | XXX | $20M | XXX | XXX | XXX |
| EV (current) | $19M | XXX | $19M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (16.1x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (14.7x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.5x | XXX | XXX | XXX |
| P/E | — | XXX | (15.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (13.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SenzaGen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SenzaGen Margins & Growth Rates
SenzaGen's revenue in the last fiscal year grew by 0%.
SenzaGen's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
SenzaGen Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (18%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 41% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 47% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 32% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 85% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SenzaGen Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SenzaGen | XXX | XXX | XXX | XXX | XXX | XXX |
| Biosynex | XXX | XXX | XXX | XXX | XXX | XXX |
| EBM Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Diagnos | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunovia | XXX | XXX | XXX | XXX | XXX | XXX |
| NanoRepro | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SenzaGen M&A Activity
SenzaGen acquired XXX companies to date.
Last acquisition by SenzaGen was on XXXXXXXX, XXXXX. SenzaGen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SenzaGen
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSenzaGen Investment Activity
SenzaGen invested in XXX companies to date.
SenzaGen made its latest investment on XXXXXXXX, XXXXX. SenzaGen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SenzaGen
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SenzaGen
| When was SenzaGen founded? | SenzaGen was founded in 2010. |
| Where is SenzaGen headquartered? | SenzaGen is headquartered in Sweden. |
| How many employees does SenzaGen have? | As of today, SenzaGen has over 34 employees. |
| Is SenzaGen publicly listed? | Yes, SenzaGen is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of SenzaGen? | SenzaGen trades under SENZA ticker. |
| When did SenzaGen go public? | SenzaGen went public in 2017. |
| Who are competitors of SenzaGen? | SenzaGen main competitors are Biosynex, EBM Technologies, Diagnos, Immunovia. |
| What is the current market cap of SenzaGen? | SenzaGen's current market cap is $20M. |
| What is the current revenue of SenzaGen? | SenzaGen's last fiscal year revenue is $6M. |
| What is the current EV/Revenue multiple of SenzaGen? | Current revenue multiple of SenzaGen is 2.9x. |
| Is SenzaGen profitable? | No, SenzaGen is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.